One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Hydrocodone | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Magnesium sulfate | The therapeutic efficacy of Botulinum toxin type B can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Botulinum toxin type B may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Mirtazapine | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Orphenadrine | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Pramipexole | Botulinum toxin type B may increase the sedative activities of Pramipexole. |
| Ropinirole | Botulinum toxin type B may increase the sedative activities of Ropinirole. |
| Rotigotine | Botulinum toxin type B may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Botulinum toxin type B. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Sodium oxybate. |
| Suvorexant | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type B. |
| Thalidomide | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type B. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Botulinum toxin type B. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Botulinum toxin type B. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Botulinum toxin type B. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Botulinum toxin type B. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum toxin type B. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Botulinum toxin type B. |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum toxin type B. |
| Butalbital | The risk or severity of adverse effects can be increased when Butalbital is combined with Botulinum toxin type B. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Botulinum toxin type B. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type B. |
| Talbutal | The risk or severity of adverse effects can be increased when Talbutal is combined with Botulinum toxin type B. |
| Pentobarbital | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum toxin type B. |
| Amitriptyline | The risk or severity of adverse effects can be increased when Amitriptyline is combined with Botulinum toxin type B. |
| Ipratropium | The risk or severity of adverse effects can be increased when Ipratropium is combined with Botulinum toxin type B. |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Botulinum toxin type B. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum toxin type B. |
| Terfenadine | The risk or severity of adverse effects can be increased when Terfenadine is combined with Botulinum toxin type B. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum toxin type B. |
| Clozapine | The risk or severity of adverse effects can be increased when Clozapine is combined with Botulinum toxin type B. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Botulinum toxin type B. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Botulinum toxin type B. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Botulinum toxin type B. |
| Profenamine | The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum toxin type B. |
| Metocurine iodide | The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Botulinum toxin type B. |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum toxin type B. |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Botulinum toxin type B. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type B. |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Botulinum toxin type B. |
| Imipramine | The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type B. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum toxin type B. |
| Metharbital | The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum toxin type B. |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Botulinum toxin type B. |
| Gallamine triethiodide | The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Botulinum toxin type B. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Botulinum toxin type B. |
| Tridihexethyl | The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Botulinum toxin type B. |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum toxin type B. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Botulinum toxin type B. |
| Anisotropine methylbromide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum toxin type B. |
| Nortriptyline | The risk or severity of adverse effects can be increased when Nortriptyline is combined with Botulinum toxin type B. |
| Amoxapine | The risk or severity of adverse effects can be increased when Amoxapine is combined with Botulinum toxin type B. |
| Lamotrigine | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Lamotrigine. |
| Cisatracurium | The risk or severity of adverse effects can be increased when Cisatracurium is combined with Botulinum toxin type B. |
| Atropine | The risk or severity of adverse effects can be increased when Atropine is combined with Botulinum toxin type B. |
| Thiopental | The risk or severity of adverse effects can be increased when Thiopental is combined with Botulinum toxin type B. |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum toxin type B. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Botulinum toxin type B. |
| Pirenzepine | The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum toxin type B. |
| Paroxetine | The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type B. |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with Botulinum toxin type B. |
| Homatropine methylbromide | The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Botulinum toxin type B. |
| Rocuronium | The risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum toxin type B. |
| Atracurium besylate | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum toxin type B. |
| Scopolamine | The risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum toxin type B. |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Botulinum toxin type B. |
| Benzquinamide | The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum toxin type B. |
| Clidinium | The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum toxin type B. |
| Propiomazine | The risk or severity of adverse effects can be increased when Propiomazine is combined with Botulinum toxin type B. |
| Propantheline | The risk or severity of adverse effects can be increased when Propantheline is combined with Botulinum toxin type B. |
| Primidone | The risk or severity of adverse effects can be increased when Primidone is combined with Botulinum toxin type B. |
| Dicyclomine | The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type B. |
| Biperiden | The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum toxin type B. |
| Brompheniramine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum toxin type B. |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Botulinum toxin type B. |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Botulinum toxin type B. |
| Quinidine | The risk or severity of adverse effects can be increased when Quinidine is combined with Botulinum toxin type B. |
| Amantadine | The risk or severity of adverse effects can be increased when Amantadine is combined with Botulinum toxin type B. |
| Maprotiline | The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type B. |
| Methantheline | The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum toxin type B. |
| Hexafluronium | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum toxin type B. |
| Cycrimine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum toxin type B. |
| Desloratadine | The risk or severity of adverse effects can be increased when Desloratadine is combined with Botulinum toxin type B. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum toxin type B. |
| Tolterodine | The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum toxin type B. |
| Oxybutynin | The risk or severity of adverse effects can be increased when Oxybutynin is combined with Botulinum toxin type B. |
| Promethazine | The risk or severity of adverse effects can be increased when Promethazine is combined with Botulinum toxin type B. |